MedTrace Logo

Anti Infective Agents Impact in COVID-19 Pneumonia

NCT04453501 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2020-07-01

No results posted yet for this study

Summary

During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone.

Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.

Conditions

Interventions

DRUG

favorable outcome

Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)

Sponsors & Collaborators

  • Centre d'Investigation Clinique et Technologique 805

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-02
Primary Completion
2020-04-25
Completion
2020-04-25
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453501 on ClinicalTrials.gov